KAHR Bio completed a USD 22 million financing to advance its Phase II clinical trial of DSP107 combined with atezolizumab for treating MSS-CRC, aiming to address a significant unmet medical need in oncology.

Information on the Target

KAHR Bio, a subsidiary of Flerie AB (publ), has made significant strides in cancer treatment through its Phase II trial involving DSP107, a novel therapeutic agent. The trial results reported a median overall survival of 17.5 months for patients suffering from advanced, chemo-refractory microsatellite-stable colorectal cancer (MSS-CRC) when DSP107 was combined with atezolizumab, an anti-PD-L1 immunotherapy. In December 2025, the company plans to enroll its first patient for an additional Phase II trial following the successful completion of a USD 22 million equity financing round.

CEO Ted Fjällman highlighted the potential of KAHR Bio's bifunctional fusion protein platform, which aims to improve cancer treatment efficacy and address significant unmet medical needs. The recent funding is designated to support a Phase IIb trial of DSP107 combined with atezolizumab, compared to fruquintinib in fourth-line metastatic MSS-CRC.

Industry Overview in the Target’s Specific Country

Microsatellite Stable Colorectal Cancer (MSS-CRC) is a critical focus in oncology, representing approximately 85% of all colorectal cancer cases. Despite the prevalence, this condition has demonstrated a notable resistance to current